These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22236988)

  • 1. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Flinn IW
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell receptor inhibition as a target for CLL therapy.
    Jeyakumar D; O'Brien S
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):2-14. PubMed ID: 27742069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
    Spaargaren M; de Rooij MF; Kater AP; Eldering E
    Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
    Foluso O; Glick A; Stender M; Jaiyesimi I
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Targeted treatment of chronic lymphocytic leukaemia].
    Niemann CU
    Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.
    Burger JA
    Curr Hematol Malig Rep; 2012 Mar; 7(1):26-33. PubMed ID: 22105489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
    Brown JR
    Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
    Choi MY; Kipps TJ
    Cancer J; 2012; 18(5):404-10. PubMed ID: 23006944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
    Mráz M; Doubek M; Mayer J
    Klin Onkol; 2013; 26(3):179-85. PubMed ID: 23763320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
    Pospisilova S; Sutton LA; Malcikova J; Tausch E; Rossi D; Montserrat E; Moreno C; Stamatopoulos K; Gaidano G; Rosenquist R; Ghia P;
    Haematologica; 2016 Mar; 101(3):263-5. PubMed ID: 26928246
    [No Abstract]   [Full Text] [Related]  

  • 13. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
    Mato A; Jauhari S; Schuster SJ
    Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapies Improve Outlook for Chronic Lymphocytic Leukemia.
    Brower V
    J Natl Cancer Inst; 2015 Dec; 107(12):djv396. PubMed ID: 26657100
    [No Abstract]   [Full Text] [Related]  

  • 17. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Kinase Inhibitors.
    Lamanna N
    Oncology (Williston Park); 2015 Jun; 29(6):443, 445. PubMed ID: 26091680
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
    Dias AL; Jain D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib-Induced Lymphocytosis: Cytological Features.
    Quintela A; Sujobert P; Callet-Bauchu E; Salles G; Baseggio L
    Acta Haematol; 2017; 137(1):55-57. PubMed ID: 27960168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.